The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC. METHODS: We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level of 5% or more. RESULTS: Among the 423 patients with a PD-L1 expression level of 5% or more, the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy (hazard ratio for disease progression or death, 1.15; 95% confidence interval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 months (hazard ratio for death, 1.02; 95% CI, 0.80 to 1.30). A total of 128 of 212 patients (60%) in the chemotherapy group received nivolumab as subsequent therapy. Treatment-related adverse events of any grade occurred in 71% of the patients who received nivolumab and in 92% of those who received chemotherapy. Treatment-related adverse events of grade 3 or 4 occurred in 18% of the patients who received nivolumab and in 51% of those who received chemotherapy. CONCLUSIONS: Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD-L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol-Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inter- and intra-driver heterogeneity are also evident following treatment with inhibitors of the immune checkpoint molecules PD-1 or PD-L1, with only ~20% of unselected NSCLC patients deriving durable clinical benefit38–43.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [39]
In the citing paper
“other features such as TMB appear to also be associated with clinical benefit to PD-1 / PD-L1 antibodies”
From Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I. O., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 758
Self-citation
Cited by
Sorted by citations
Items 701–800 of 1,001
Yang, L., Li, A., Yu, W., Wang, H., Zhang, L., Wang, Y., Wang, Y., Zhang, R., Lei, Q., Liu, Z., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101175 · Cited by 40
Kwong, F. N. K., Laggner, U., McKinney, O., Croud, J., Rice, A. J., & Nicholson, A. G. (2018) · Histopathology · doi:10.1111/his.13466 · Cited by 40
Fruhwirth, G. O., Kneilling, M., de Vries, I. J. M., Weigelin, B., Srinivas, M., & Aarntzen, E. H. J. G. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1254-3 · Cited by 42
Tian, W., Shan, B., Zhang, Y., Ren, Y., Liang, S., Zhao, J., Zhao, Z., Wang, G., Zhao, X., Peng, D., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2849 · Cited by 40
Gomes, F., Wong, M. L., Battisti, N. M. L., Kordbacheh, T., Kiderlen, M., Greystoke, A., & Luciani, A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0986-4 · Cited by 41
Nesline, M., Knight, T. G., Colman, S., & Patel, K. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.06.018 · Cited by 39
Kaira, K., Kuji, I., & Kagamu, H. (2021) · Cancer Imaging · doi:10.1186/s40644-021-00381-y · Cited by 40
Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma
Chiaro, J., Kasanen, H. H. E., Whalley, T., Capasso, C., Grönholm, M., Feola, S., Peltonen, K., Hamdan, F., Hernberg, M., Mäkelä, S., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0814 · Cited by 40
Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy
Tian, L., Lei, A., Tan, T., Zhu, M., Zhang, L., Mou, H., & Zhang, J. (2021) · Kidney Diseases · doi:10.1159/000518664 · Cited by 41
Insa, A., Martín-Martorell, P., Liello, R. D., Fasano, M., Martini, G., Napolitano, S., Vicidomini, G., Cappabianca, S., Franco, R., Morgillo, F., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103538 · Cited by 42
Federico, A. D., Giglio, A. D., Gelsomino, F., Sperandi, F., Melotti, B., & Ardizzoni, A. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac205 · Cited by 40
Biomarkers for hepatocellular carcinoma: What’s new on the horizon?
Ocker, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i35.3974 · Cited by 39
Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer
Lü, J., Zhong, H., Wu, J., Chu, T., Zhang, L., Li, H., Wang, Q., Li, R., Zhao, Y., Gu, A., et al. (2019) · Advanced Science · doi:10.1002/advs.201900721 · Cited by 38
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
Wakabayashi, G., Lee, Y., Luh, F., Kuo, C.-N., Chang, W., & Yen, Y. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0588-8 · Cited by 39
Zhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 40
Jin, R., Zhao, J., Xia, L., Li, Q., Li, W., Peng, L., & Xia, Y. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920930333 · Cited by 39
Akhbariyoon, H., Azizpour, Y., Esfahani, M. F., Firoozabad, M. S. M., Rad, M. R., Esfahani, K. S., Khoshavi, N., Karimi, N., Shirinisaz, A., Abedi, F., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108873 · Cited by 40
Bie, F., Tian, H., Sun, N., Zang, R., Zhang, M., Song, P., Liu, L., Peng, Y., Bai, G., Zhou, B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.769124 · Cited by 39
Tamiya, Y., Nakai, T., Suzuki, A., Mimaki, S., Tsuchihara, K., Sato, K. A., Yoh, K., Matsumoto, S., Zenke, Y., Nosaki, K., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.11.001 · Cited by 38
Sholl, L. M., Awad, M., Basu Roy, U., Beasley, M. B., Cartun, R. W., Hwang, D. M., Kalemkerian, G., Lopez-Rios, F., Mino-Kenudson, M., Paintal, A., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0536-cp · Cited by 38
Nanotechnology for immuno-oncology
Grippin, A., Lee, D., Parkes, E. E., Jiang, W., & Kim, B. Y. S. (2025) · Nature Cancer · doi:10.1038/s43018-025-01025-x · Cited by 48
Tseng, J., Yang, T., Wu, C., Ku, W., Chen, K., Hsu, K.-H., Huang, Y.-H., Su, K., Yu, S., & Chang, G. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000226 · Cited by 39
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva
Thangarajah, F., Morgenstern, B., Pahmeyer, C., Schiffmann, L. M., Puppe, J., Mallmann, P. K., Hamacher, S., Buettner, R., Alidousty, C., Holz, B., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02915-1 · Cited by 38
Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed
Levinson, K. L., Dorigo, O., Rubin, K. M., & Moore, K. N. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237967 · Cited by 38
Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm
Berghmans, T., Dingemans, A. C., Hendriks, L. E. L., & Cadranel, J. L. (2020) · European Respiratory Journal · doi:10.1183/13993003.01907-2019 · Cited by 38
Zhao, J., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000710 · Cited by 40
Bi, G., Chen, Z., Yang, X., Liang, J., Hu, Z., Bian, Y., Sui, Q., Li, R., Zhan, C., & Fan, H. X. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02546-3 · Cited by 38
Steeghs, E. M. P., Kroeze, L. I., Tops, B. B. J., van Kempen, L. C. L. T., ter Elst, A., van Raaij, A. W. M., Hendriks-Cornelissen, S. J. B., Hermsen, M. J. W., Jansen, E. A. M., Nederlof, P. M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06785-6 · Cited by 37
Zhang, Z., Zhang, F., Yuan, F., Li, Y., Ma, J., Ou, Q., Liu, Z., Yang, B. Y., Wang, L., Tao, H., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920970049 · Cited by 38
Sadeghirad, H., Bazaz, S. R., Monkman, J. H., Warkiani, M. E., Rezaei, N., O'Byrne, K. J., & Kulasinghe, A. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1215 · Cited by 37
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
Xiong, A., Wang, J., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.757993 · Cited by 38
Xu, S., Shukuya, T., Tamura, J., Shimamura, S., Kurokawa, K., Miura, K., Miyawaki, T., Hayakawa, D., Asao, T., Yamamoto, K., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100309 · Cited by 38
Pembrolizumab for all PD-L1-positive NSCLC
Smit, E. F., & Langen, A. J. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32559-5 · Cited by 37
Song, Y., Huang, J., Liang, D., Hu, Y., Mao, B., Li, Q., Sun, H., Yang, Y., Zhang, J., Zhang, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.549777 · Cited by 40
Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
Yang, J., Yan, H., Zhang, Y.-X., Zhang, M., Ji, B., Tian, G., Guo, Y., Tang, M., Li, L., Guo, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.725938 · Cited by 37
Wang, Z., Wang, X., Yuan, J., Zhang, X., Zhou, J., Lu, M. S., Liu, D., Li, J., & Shen, L. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.12.005 · Cited by 37
Lung cancer, elderly and immune checkpoint inhibitors
Casaluce, F., Sgambato, A., Maione, P., Spagnuolo, A., & Gridelli, C. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.90 · Cited by 37
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
Villanueva, N., & Bazhenova, L. A. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618794133 · Cited by 37
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects
Long, L., Zhao, C., Muqimova, O., Zhao, X., Yang, J. L., & Chen, H. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-018-00746-5 · Cited by 33
Rosenberg, T., Montgomery, P. R., Hay, V., & Lattimer, R. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-032712 · Cited by 36
Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications
Ryan, M. J., & Bose, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01287 · Cited by 40
Nie, W., Qian, J., Xu, M., Gu, K., Qian, F., Hu, M., Lü, J., Gan, L., Zhang, X., Cao, S., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1731072 · Cited by 37
Kabiljo, J., Laengle, J., & Bergmann, M. M. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0284-1 · Cited by 36
Brito, A. B. C., Camandaroba, M. P. G., & de Lima, V. C. C. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13867 · Cited by 39
Zhang, N., Guoqing, W., Yu, X., Mi, Y., Xin, H., Li, X., & Wang, R. (2021) · BioMed Research International · doi:10.1155/2021/1780860 · Cited by 37
Current Challenges for IDO2 as Target in Cancer Immunotherapy
Mondanelli, G., Mandarano, M., Belladonna, M. L., Suvieri, C., Pelliccia, C., Bellezza, G., Sidoni, A., Carvalho, A., Grohmann, U., & Volpi, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679953 · Cited by 38
Sanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Abolghasemi, H., Ghaffari, S. H., Momeny, M., & Bashash, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174404 · Cited by 36
Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
Luo, W., Wang, Z., Zhang, T., Yang, L., Xian, J., Li, Y., & Li, W. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab027 · Cited by 40
Liquid Biopsy: the Value of Different Bodily Fluids
Santos, V., Freitas, C., Fernandes, M. G., Sousa, C., Reboredo, C., Martins, N. A., Mosquera, J., Hespanhol, V. P., & Campelo, R. G. (2022) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0370 · Cited by 39
Zhou, L., Xiong, Y., Wang, Y., Meng, Y. G., Zhang, W., Shen, M., Zhang, X., Li, S., Ren, B., Li, R., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.009 · Cited by 36
The emerging treatment landscape of advanced non-small cell lung cancer
Economopoulou, P., & Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.07 · Cited by 36
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer
Melosky, B. L., Juergens, R. A., McLeod, D., Leighl, N. B., Brade, A. M., Card, P. B., & Chu, Q. S.-C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.027 · Cited by 34
Self-citationJang, H.-J., Lee, H., Ramos, D., Park, I. K., Kang, C. H., Burt, B. M., & Kim, Y. T. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.10.123 · Cited by 35
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
Hu, Z., Li, M., Chen, Z., Zhan, C., Lin, Z., & Wang, Q. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.10.17 · Cited by 36
Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement
Budczies, J., Kazdal, D. N., Allgäuer, M., Christopoulos, P., Rempel, E., Pfarr, N., Weichert, W., Fröhling, S., Thomas, M., Peters, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.01.019 · Cited by 36
Self-citationEffectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
Yang, Y., Yu, Y., & Lü, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-019-1622-5 · Cited by 37
Gobbini, É., Swalduz, A., Levra, M. G., Ortiz‐Cuaran, S., Toffart, A., Pérol, M., Moro‐Sibilot, D., & Saintigny, P. (2020) · Cancers · doi:10.3390/cancers12113112 · Cited by 36
2020 Innovation-Based Optimism for Lung Cancer Outcomes
Schenk, E. L., Patil, T., Pacheco, J. M., & Bunn, P. A. (2020) · The Oncologist · doi:10.1002/onco.13590 · Cited by 37
Next-generation sequencing for the management of sarcomas with no known driver mutations
Vyse, S., Thway, K., Huang, P. H., & Jones, R. L. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000741 · Cited by 36
Li, L., Lu, G., Liu, Y., Gong, L., Zheng, X. Y., Zheng, H., Gu, W., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658690 · Cited by 39
Lu, M., Xu, J., Ye, Y., Wang, Y., Luo, S., & Gong, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.723609 · Cited by 36
Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma
Aroldi, F., & Middleton, M. R. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00681-4 · Cited by 34
Hasegawa, H., Shitara, K., Takiguchi, S., Takiguchi, N., Ito, S., Kochi, M., Horinouchi, H., Kinoshita, T., Yoshikawa, T., Muro, K., et al. (2022) · Gastric Cancer · doi:10.1007/s10120-022-01286-w · Cited by 37
The role of neoantigens in tumor immunotherapy
Shang, S., Zhao, Y., Qian, K., Qin, Y., Zhang, X., Li, T., Shan, L., Wei, M., Xi, J., & Tang, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113118 · Cited by 37
Zhao, C., Jiang, T., Ju, J. H., Zhang, S., Tao, J., Fu, Y. S., LoCoco, J. S., Dockter, J., Pawlowski, T. L., & Bilke, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.21.349100 · Cited by 35
Vardarli, I., Tan, S., Brandenburg, T., Weidemann, F., Görges, R., Herrmann, K., & Führer, D. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad670 · Cited by 40
Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients
Garon, E. B. (2017) · New England Journal of Medicine · doi:10.1056/nejme1705692 · Cited by 35
Early Detection and Chemoprevention of Lung Cancer
New, M. L., & Keith, R. L. (2018) · F1000Research · doi:10.12688/f1000research.12433.1 · Cited by 35
Ackermann, C. J., Reck, M., Paz-Ares, L. G., Barlési, F., & Califano, R. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.007 · Cited by 35
Self-citationChromosomal rearrangements and their neoantigenic potential in mesothelioma
Mansfield, A. S., Peikert, T., & Vasmatzis, G. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.12 · Cited by 35
Huang, D., Zhang, F., Tao, H., Zhang, S., Ma, J., Wang, J., Liu, Z., Cui, P., Chen, S., Huang, Z., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00703-3 · Cited by 35
Advances in theranostic biomarkers for tumor immunotherapy
Bellesœur, A., Torossian, N., Amigorena, S., & Romano, E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.005 · Cited by 34
Chen, Y., Hu, J., Bu, F., Zhang, H., Fei, K., & Zhang, P. (2020) · BMC Cancer · doi:10.1186/s12885-020-07206-4 · Cited by 35
Xie, F., Bai, Y., Yang, X., Long, J., Mao, J., Lin, J., Wang, D., Song, Y., Xun, Z., Huang, H., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107135 · Cited by 37
Wang, X., Niu, X., An, N., Sun, Y., & Chen, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.611012 · Cited by 36
Ramos‐Paradas, J., Hernández-Prieto, S., Lora, D., Sanchez, E., Rosado, A., Caniego-Casas, T., Carrizo, N., Enguita, A. B., Muñoz-Jimenez, M. T., Rodriguez, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001904 · Cited by 35
Self-citationBackman, M., Fleur, L. L., Kurppa, P., Djureinovic, D., Elfving, H., Brunnström, H., Mattsson, J. S. M., Lindberg, A., Pontén, V., Eltahir, M., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5772 · Cited by 33
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 38
Sun, Y.-M., Wang, Y., Sun, X.-X., Chen, J., Gong, Z.-P., & Meng, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.558454 · Cited by 34
Clinical predictive value of naïve and memory T cells in advanced NSCLC
Zhang, G., Liu, A., Yang, Y., Xia, Y., Li, W., Liu, Y., Zhang, J., Cui, Q., Wang, D., Liu, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996348 · Cited by 35
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Jung, C. Y., & Antonia, S. J. (2018) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2017.0120 · Cited by 34
Ma, G., Deng, Y., Jiang, H., Li, W., Wu, Q., & Zhou, Q. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.03.038 · Cited by 34
Xu, J., Guo, X., Jing, M., & Sun, T. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s159830 · Cited by 34
Togasaki, K., Sukawa, Y., Kanai, T., & Takaishi, H. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s152514 · Cited by 32
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Vargas, T. R., & Apétoh, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01181 · Cited by 37
Heeke, S., Benzaquen, J., Long-Mira, É., Audelan, B., Lespinet‐Fabre, V., Bordone, O., Lalvée, S., Zahaf, K., Poudenx, M., Humbert, O., et al. (2019) · Cancers · doi:10.3390/cancers11091271 · Cited by 35
Hader, M., Savcigil, D. P., Rosin, A., Ponfick, P., Gekle, S., Wadepohl, M., Bekeschus, S., Fietkau, R., Frey, B., Schlücker, E., et al. (2020) · Cancers · doi:10.3390/cancers12051082 · Cited by 34
Efficacy of Immune Checkpoint Inhibitors and Age in Cancer Patients
Huang, X., Gao, P., Song, Y., Sun, J., Chen, X., Zhao, J., & Wang, Z. (2020) · Immunotherapy · doi:10.2217/imt-2019-0124 · Cited by 36
Medjebar, S., Truntzer, C., Perrichet, A., Limagne, E., Fumet, J.-D., Richard, C., Elkrief, A., Routy, B., Rébé, C., & Ghiringhelli, F. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1836766 · Cited by 34
The Impact of Estrogen in the Tumor Microenvironment
Somasundaram, A., Rothenberger, N. J., & Stabile, L. P. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50224-9_2 · Cited by 36
Liu, S., Wu, F., Li, X., Zhao, C., Jia, Y., Jia, K., Han, R., Qiao, M., Li, W., Yu, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639947 · Cited by 36
Chi, A., He, X., Hou, L., Nguyen, N. P., Zhu, G., Cameron, R. B., & Lee, J. M. (2021) · Cancers · doi:10.3390/cancers13122924 · Cited by 36
Zeng, Z., Li, J., Zhang, J., Li, Y., Liu, X., Chen, J., Huang, Z., Wu, Q., Gong, Y. Q., & Xie, C. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03002-1 · Cited by 34
Liu, Y., Xu, Y., Cheng, X., Lin, Y., Jiang, S., Yu, H., Zhang, Z., Lu, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862084 · Cited by 36
Lee, B., Park, S. J., Lee, S., Lee, J. W., Lee, E., Yoo, E.-S., Chung, W., Sohn, J., Oh, B., & Kim, S. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05039-6 · Cited by 33
Zhao, Y., Liu, Y., Jia, Y., Wang, X., He, J., Zhen, S., Wang, J., & Liu, L. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04250-4 · Cited by 34
Liao, C.-Y., Chen, Y., Wu, Y., Chao, H., Chiu, H., Wang, T., Chen, J.-R., Shiao, T., & Lu, C. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00779-4 · Cited by 35
Overview of Ongoing Clinical Trials Investigating Combined Radiotherapy and Immunotherapy
Cushman, T. R., Caetano, M. S., Welsh, J. W., & Verma, V. (2018) · Immunotherapy · doi:10.2217/imt-2018-0019 · Cited by 33
Bockel, S., Durand, B., & Deutsch, É. (2018) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2018.07.136 · Cited by 36
Yang, W., Li, S., & Yang, Q. (2019) · Medicine · doi:10.1097/md.0000000000015731 · Cited by 33
Metadata
- Authors
- Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., Ready, N., Hiltermann, T. J. N., Nair, S., Juergens, R., Peters, S., Minenza, E., Wrangle, J. M., Rodriguez-Abreu, D., Borghaei, H., Blumenschein, G. R., Villaruz, L. C., Havel, L., Krejci, J., Corral Jaime, J., Chang, H., Geese, W. J., Bhagavatheeswaran, P., Chen, A. C., & Socinski, M. A.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Carbone, David P.
- Reck, Martin
- Paz-Ares, Luis
- Horn, Leora
- Felip, Enriqueta
- Ciuleanu, Tudor-Eliade
- Badin, Firas
- Ready, Neal
- Hiltermann, T. Jeroen N.
- Nair, Suresh
- Juergens, Rosalyn
- Peters, Solange
- Wrangle, John M.
- Borghaei, Hossein
- Blumenschein, George R.
- Villaruz, Liza C.
- Havel, Libor
- Chang, Han
- Geese, William J.
- Socinski, Mark A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-06-22
- Volume
- 376
- Issue
- 25
- Pages
- 2415-2426
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6487310
- OpenAlex
- W2635951006
- Cited by
- 2,503
- References
- 20
- Citations by year
- 2026: 54 · 2025: 121 · 2024: 196 · 2023: 223 · 2022: 328 · 2021: 380 · 2020: 432 · 2019: 372 · 2018: 334 · 2017: 61
- FWCI
- 144.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- IRIS (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lirias (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (UG1CA233259, K12CA157688, P30CA016672, P30CA016058)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, non-small cell lung cancer, PD-L1 expression, first-line therapy, stage IV NSCLC, recurrent NSCLC, platinum-based chemotherapy, docetaxel, progression-free survival, overall survival, immune checkpoint inhibitors, treatment-related adverse events, PD-1 inhibitors, PD-L1 inhibitors, PD-1/PD-L1 blockade
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Disease-Free Survival, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
